Is the future of COVID-19 vaccine sprays?
Dozens of research groups and companies are working on new types of vaccine. These sprays or drops are administered through the nose or mouth to improve protection against the virus.
The Chinese company CanSino Biologics was approved for use of a booster dose of the vaccine in China.
There are more than 100 oral or nasal vaccines in development. In theory, these vaccines could prime immune cells in the thin mucus membranes that line the nose and mouth and stop the spread of the disease before it happens. The developers of the vaccine hope that they will be able to prevent mild cases of illness and block transmission to other people. The sprayable vaccine against flu is one of the few mucosal vaccines approved for other diseases.
The idea of sterilizing immunity is supported by evidence in animals. What the latest findings mean is explained by Nature.
The COVID-19 vaccines do a good job of reducing disease severity but don't block mild illness or transmission.
They are injected into muscles. T cells, which destroy infections, and B cells, which neutralize pathogens, are produced by the immune system after a vaccine is given. The cells circulate through the body. They aren't present at high enough levels in the nose and lungs to give rapid protection In the time it takes for them to get there from the bloodstream, the virus can spread and cause illness.
Mucosal vaccines can cause an immune response in the whole body, but they can also cause an immune response in the nose and respiratory Tract. Benjamin Goldman-Israelow is a physician-scientist at the Yale School of Medicine. They can act fast.
The circulating T cells and B cells have the same function as the tissue-resident memory T and B cells. The secretory immunoglobulin A (IgA), which is produced by tissue-resident memory B cells, can be used to stop diseases. It's not clear how well secretory IgA will protect against the disease.
Unvaccinated people and people who have already received a COVID-19 shot are being tested for vaccine boosters. There are some vaccines that are squirted up the nose. Some people have a different composition. CanSino's mucosal vaccine is the same as its injected one, but is packaged into aerosols and inhaled through the mouth with a nebulizer at one-fifth the dose. Some vaccines are taken as pills.
The firm Codagenix has a vaccine that can be dropped up the nose. Clinical trials are where it is located. The institute of India has a credit.
There are at least nine vaccines approved to be used in people against diseases. One of the vaccines is administered through the nose.
The oral vaccine is very successful in inducing immunity in the gut. This vaccine can cause illness in rare cases. Sometimes the vaccine doesn't generate a sufficiently strong immune response and sometimes it causes side effects. Berna Biotech pulled its flu vaccine off the market in 2001 after it was found to increase the risk of facial paralysis.
The FluMist vaccine is approved in the United States and Europe and is better for young children than the injected vaccine. It is more convenient for adults to have a vaccine sprayed up their noses. FluMist isn't as effective in adults as it is in children. Many have been exposed to the flu for a long time. Even if this immunity isn't strong enough to prevent the disease, adults may still block the vaccine from infecting nasal cells or clear it before it has a chance to do its job.
The director of the World Health Organization's Collaborating Centre for Reference says it's a balancing act between making sure the vaccine doesn't cause illness and replicating enough to give people immunity. Researchers don't know if the issue affects the COVID-19 vaccine.
According to Airfinity, a health-analytics company in London, around 100 COVID-19 vaccines are in development. At least four of those have completed or are in the process of completing phase III studies to test safety and how well they work compared to other vaccines. Ali Es-haghi, an analytical chemist at the Razi Vaccine and Serum Research Institute in Karaj, said that at least five million doses of the vaccine have been delivered to the Ministry of Health. The institute hasn't published data on effectiveness in humans. Russia is said to have approved a vaccine but has not published data and the vaccine makers did not respond to a request for details.
It will take at least a year or two for large-scale human trial data to be available. Louise Blair is the head of vaccines and variant at Airfinity. There is a lot of vaccines. Protection against hospitalization seems to be the preferred option for countries at the moment. Funding and resources are different and I don't think we'll see the same speed of development
The countries have to rely on boosters to maintain immunity. Early data suggests that boosters against Omicron are slightly better than an extra dose of older vaccines. Robert Seder is the chief of cellular immunology at the US National Institute of Allergy and Infectious Diseases. Changing the delivery of boosters could increase protection against transmission.
Any vaccine needs to be able to prevent infections and transmission. Studies show that it is possible. A study 2 in mice by Goldman-Israelow and his colleagues at Yale University found that a booster after a single dose of a vaccine protects the animals from a fatal level of exposure to the coronaviruses.
In rhesus macaques, the vaccine used to protect the animals from the disease was similar to the one used to protect humans from the flu. The monkeys had no evidence of virus replication in their lungs or airways. There is a model that is very close to sterilizing immunity. She says that they will have to see how thistranslates into clinical studies.
Measure the neutralizing-antibody levels in the blood to see if the vaccine will work. Researchers have known for decades that higher levels mean better protection.
There is no clear-cut correlate for vaccines that aim to induce immunity. Immune responses in the respiratory tract are being measured by many developers. It is not clear what levels are needed to prevent transmission and infections. It is possible that studies of immune responses in the nose and lungs of people who have experienced natural infections will be informative.
The efficacy of the vaccine must be determined in other ways. In its trial of the COVID-19 vaccine, the company measured systemic neutralizing antibodies in the blood of participants. The trial will be considered a success if the trial matches or exceeds the levels of the vaccine on the market. The vaccine's ability to prevent infections won't be determined by it. Last month, the firm said it had sent late-stage testing data to the country's regulators, hoping for approval to start giving the vaccine to clinics.
CanSino used the same strategy to track efficacy, measuring the levels of neutralizing antibodies in blood and comparing them to those from existing vaccines. A phase II study of the company's aerosolized mucosal vaccine reported in January that when given as a booster, it raised the vaccine's effectiveness more than CanSino's vaccine. The firm reported in July that the levels of antibody waned over time, but were still higher than those elicited through the route. Levels of response needed to provide sterilizing immunity aren't known.
Beijing Wantai Biological Pharmacy did not respond to Nature's request for comment on their vaccine trials.
It's possible to compare a vaccine against a placebo. In a phase II/III study of a vaccine in 20,000 unvaccinated people, Codagenix and the Serum Institute of India will give placebos to half of them. Efficacy will be determined by comparing the number of confirmed cases in each group and the rate of protection from the vaccine, according to Robert Coleman, chief executive at Codagenix.
As the number of people who have not been exposed to the disease dwindles, placebo groups are becoming harder to assemble. It's difficult to justify ethically when effective vaccines are available. There are countries with low vaccination rates and limited vaccine access that can be used to conduct an ethical trial. The WHO's Solidarity Trial Vaccines bring several trials together to share one placebo group. There are trials being conducted in Africa to start with, but no details have been given. They aren't expected to produce results until later in the decade. The trial of the vaccine as a booster is currently in the first stage.
Sandy Douglas says that it is possible to determine the efficacy of a vaccine. He says it is a bit more difficult than testing first- generation vaccine in an infection-naive population.
Nature 609 and 243.
All Rights Reserved © 2024
